Fortress Biotech (FBIO) CFO adds 2,967 ESPP shares in exempt grant

Rhea-AI Filing Summary

Fortress Biotech, Inc. Chief Financial Officer David Jin acquired 2,967 shares of common stock at $2.176 per share through the company’s Employee Stock Purchase Plan. This grant was reported as exempt under Rule 16b-3(d) and Rule 16b-3(c). After the transaction, he holds 1,251,571 shares in total, including 1,230,000 shares underlying deferred restricted stock units, so the new purchase represents a small portion of his overall position.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Jin David

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock, par value $0.001	2,967	$2.176	$6K

Holdings After Transaction: Common Stock, par value $0.001 — 1,251,571 shares (Direct)

Footnotes (1)

1. The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Total holdings include 1,230,000 shares underlying deferred restricted stock units.

Key Figures

Shares acquired: 2,967 shares Acquisition price: $2.176 per share Total shares after transaction: 1,251,571 shares +1 more

4 metrics

Shares acquired 2,967 shares Employee Stock Purchase Plan grant to CFO David Jin

Acquisition price $2.176 per share Price for ESPP shares acquired on 2026-04-01

Total shares after transaction 1,251,571 shares CFO David Jin’s holdings following the grant

Deferred RSU underlying shares 1,230,000 shares Included within total holdings as deferred restricted stock units

Key Terms

Employee Stock Purchase Plan, Rule 16b-3(d), Rule 16b-3(c), deferred restricted stock units

4 terms

Employee Stock Purchase Plan financial

"an acquisition of shares under the Issuer's Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

Rule 16b-3(d) regulatory

"a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)"

Rule 16b-3(c) regulatory

"a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c)"

An SEC rule that lets corporate insiders avoid automatic "short‑swing" profit recovery when they buy or sell their company’s stock under a pre‑approved, written plan that meets specific conditions. For investors, it matters because it clarifies when insider trades are treated as routine, reducing legal uncertainty and helping distinguish trades made for ordinary compensation or pre‑planned reasons from those that might signal opportunistic or timely insider advantage.

deferred restricted stock units financial

"Total holdings include 1,230,000 shares underlying deferred restricted stock units"

Deferred restricted stock units are promises by a company to give employees or executives company shares at a future date, subject to conditions like continued employment or performance targets; the delivery and tax event are intentionally delayed. They matter to investors because they affect when new shares may be issued and how executives are motivated—like a paycheck held in escrow that vests over time, influencing potential share dilution and management behavior.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Jin David

(Last) (First) (Middle)

C/O FORTRESS BIOTECH, INC.

1111 KANE CONCOURSE SUITE 301

(Street)

BAY HARBOR ISLANDS FLORIDA 33154

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Fortress Biotech, Inc. [ FBIO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.001	04/01/2026		A	V	2,967(1)	A	$2.176	1,251,571(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reporting person is voluntarily reporting an acquisition of shares under the Issuer's Employee Stock Purchase Plan in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).

2. Total holdings include 1,230,000 shares underlying deferred restricted stock units.

	/s/ David Jin	04/01/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Fortress Biotech (FBIO) report for its CFO?

Fortress Biotech reported that CFO David Jin acquired 2,967 shares of common stock through the company’s Employee Stock Purchase Plan. The shares were obtained at a price of $2.176 per share and were characterized as a grant or award acquisition rather than an open-market purchase.

How many Fortress Biotech (FBIO) shares does the CFO hold after this Form 4?

After the reported transaction, CFO David Jin holds 1,251,571 shares of Fortress Biotech common stock. This total includes 1,230,000 shares underlying deferred restricted stock units, meaning the newly acquired 2,967 shares add only a small increment to an already large position.

Was the Fortress Biotech (FBIO) CFO’s share acquisition an open-market buy?

No. The acquisition of 2,967 Fortress Biotech shares by CFO David Jin was made under the company’s Employee Stock Purchase Plan. It is reported as a grant or award acquisition and was exempt under Rule 16b-3(d) and Rule 16b-3(c), not an open-market purchase.

What is notable about the rules cited for the Fortress Biotech (FBIO) CFO’s transaction?

The filing notes that the CFO’s acquisition under the Employee Stock Purchase Plan was exempt under Rule 16b-3(d) and Rule 16b-3(c). These provisions generally cover board-approved, issuer-sponsored plans, framing the transaction as routine compensation-related activity rather than discretionary market trading.

How significant is the 2,967-share acquisition for Fortress Biotech (FBIO)’s CFO holdings?

The 2,967-share acquisition is relatively small compared with CFO David Jin’s total holdings of 1,251,571 shares. Because those holdings already include 1,230,000 shares underlying deferred restricted stock units, the new Employee Stock Purchase Plan shares represent a minor increase in his overall exposure.